Published by Josh White on 14th January 2026
(Sharecast News) - Truetide said on Wednesday that its wholly-owned subsidiary Paraytec had launched a focused development programme aimed at establishing a high-throughput, real-time fluorescent assay to study alpha-synuclein fibril formation, targeting a key bottleneck in Parkinson's disease drug discovery.